vs
Certara, Inc.（CERT）与Esperion Therapeutics, Inc.（ESPR）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是Certara, Inc.的1.6倍（$168.4M vs $103.6M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 3.3%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 3.6%）
Certara是全球领先的生物制药软件及咨询服务提供商，专注于建模模拟、监管科学领域的解决方案，服务药企、生物技术企业及医疗相关方，覆盖药物研发全周期，助力加快新疗法上市，降低研发风险与综合成本。
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
CERT vs ESPR — 直观对比
营收规模更大
ESPR
是对方的1.6倍
$103.6M
营收增速更快
ESPR
高出140.5%
3.3%
两年增速更快
ESPR
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $103.6M | $168.4M |
| 净利润 | $-5.9M | — |
| 毛利率 | — | — |
| 营业利润率 | 0.8% | 50.6% |
| 净利率 | -5.7% | — |
| 营收同比 | 3.3% | 143.7% |
| 净利润同比 | -189.6% | — |
| 每股收益（稀释后） | $-0.04 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CERTESPR
| Q4 25 | $103.6M | $168.4M | ||
| Q3 25 | $104.6M | $87.3M | ||
| Q2 25 | $104.6M | $82.4M | ||
| Q1 25 | $106.0M | $65.0M | ||
| Q4 24 | $100.4M | $69.1M | ||
| Q3 24 | $94.8M | $51.6M | ||
| Q2 24 | $93.3M | $73.8M | ||
| Q1 24 | $96.7M | $137.7M |
净利润CERTESPR
| Q4 25 | $-5.9M | — | ||
| Q3 25 | $1.5M | $-31.3M | ||
| Q2 25 | $-2.0M | $-12.7M | ||
| Q1 25 | $4.7M | $-40.5M | ||
| Q4 24 | $6.6M | — | ||
| Q3 24 | $-1.4M | $-29.5M | ||
| Q2 24 | $-12.6M | $-61.9M | ||
| Q1 24 | $-4.7M | $61.0M |
营业利润率CERTESPR
| Q4 25 | 0.8% | 50.6% | ||
| Q3 25 | 2.9% | -11.4% | ||
| Q2 25 | 9.1% | 8.6% | ||
| Q1 25 | 7.2% | -34.0% | ||
| Q4 24 | 6.0% | -6.4% | ||
| Q3 24 | 2.7% | -31.0% | ||
| Q2 24 | -9.7% | 3.5% | ||
| Q1 24 | -1.3% | 52.5% |
净利率CERTESPR
| Q4 25 | -5.7% | — | ||
| Q3 25 | 1.5% | -35.9% | ||
| Q2 25 | -1.9% | -15.4% | ||
| Q1 25 | 4.5% | -62.2% | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | -1.4% | -57.2% | ||
| Q2 24 | -13.5% | -83.9% | ||
| Q1 24 | -4.8% | 44.3% |
每股收益（稀释后）CERTESPR
| Q4 25 | $-0.04 | $0.32 | ||
| Q3 25 | $0.01 | $-0.16 | ||
| Q2 25 | $-0.01 | $-0.06 | ||
| Q1 25 | $0.03 | $-0.21 | ||
| Q4 24 | $0.04 | $-0.14 | ||
| Q3 24 | $-0.01 | $-0.15 | ||
| Q2 24 | $-0.08 | $-0.33 | ||
| Q1 24 | $-0.03 | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $189.4M | $167.9M |
| 总债务越低越好 | $293.1M | — |
| 股东权益账面价值 | $1.1B | $-302.0M |
| 总资产 | $1.6B | $465.9M |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
现金及短期投资CERTESPR
| Q4 25 | $189.4M | $167.9M | ||
| Q3 25 | $172.7M | $92.4M | ||
| Q2 25 | $162.3M | $86.1M | ||
| Q1 25 | $179.1M | $114.6M | ||
| Q4 24 | $179.2M | $144.8M | ||
| Q3 24 | $233.0M | $144.7M | ||
| Q2 24 | $224.6M | $189.3M | ||
| Q1 24 | $224.8M | $226.6M |
总债务CERTESPR
| Q4 25 | $293.1M | — | ||
| Q3 25 | $293.5M | — | ||
| Q2 25 | $294.2M | — | ||
| Q1 25 | $294.8M | — | ||
| Q4 24 | $295.4M | — | ||
| Q3 24 | $296.1M | — | ||
| Q2 24 | $296.7M | — | ||
| Q1 24 | $290.8M | — |
股东权益CERTESPR
| Q4 25 | $1.1B | $-302.0M | ||
| Q3 25 | $1.1B | $-451.4M | ||
| Q2 25 | $1.1B | $-433.5M | ||
| Q1 25 | $1.1B | $-426.2M | ||
| Q4 24 | $1.1B | $-388.7M | ||
| Q3 24 | $1.1B | $-370.2M | ||
| Q2 24 | $1.0B | $-344.2M | ||
| Q1 24 | $1.1B | $-294.3M |
总资产CERTESPR
| Q4 25 | $1.6B | $465.9M | ||
| Q3 25 | $1.5B | $364.0M | ||
| Q2 25 | $1.5B | $347.1M | ||
| Q1 25 | $1.6B | $324.0M | ||
| Q4 24 | $1.6B | $343.8M | ||
| Q3 24 | $1.5B | $314.1M | ||
| Q2 24 | $1.5B | $352.3M | ||
| Q1 24 | $1.5B | $373.1M |
负债/权益比CERTESPR
| Q4 25 | 0.28× | — | ||
| Q3 25 | 0.28× | — | ||
| Q2 25 | 0.27× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | 0.28× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.8M | $45.2M |
| 自由现金流经营现金流 - 资本支出 | $27.8M | — |
| 自由现金流率自由现金流/营收 | 26.8% | — |
| 资本支出强度资本支出/营收 | 1.0% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $94.4M | — |
8季度趋势，按日历期对齐
经营现金流CERTESPR
| Q4 25 | $28.8M | $45.2M | ||
| Q3 25 | $32.3M | $-4.3M | ||
| Q2 25 | $17.8M | $-31.4M | ||
| Q1 25 | $17.4M | $-22.6M | ||
| Q4 24 | $49.4M | $-35.0M | ||
| Q3 24 | $17.0M | $-35.3M | ||
| Q2 24 | $9.8M | $-7.2M | ||
| Q1 24 | $4.3M | $53.8M |
自由现金流CERTESPR
| Q4 25 | $27.8M | — | ||
| Q3 25 | $32.1M | — | ||
| Q2 25 | $17.8M | — | ||
| Q1 25 | $16.8M | — | ||
| Q4 24 | $49.0M | — | ||
| Q3 24 | $16.8M | $-35.5M | ||
| Q2 24 | $9.4M | $-7.3M | ||
| Q1 24 | $3.7M | $53.8M |
自由现金流率CERTESPR
| Q4 25 | 26.8% | — | ||
| Q3 25 | 30.7% | — | ||
| Q2 25 | 17.0% | — | ||
| Q1 25 | 15.8% | — | ||
| Q4 24 | 48.8% | — | ||
| Q3 24 | 17.7% | -68.7% | ||
| Q2 24 | 10.1% | -9.9% | ||
| Q1 24 | 3.8% | 39.0% |
资本支出强度CERTESPR
| Q4 25 | 1.0% | 0.0% | ||
| Q3 25 | 0.2% | 0.0% | ||
| Q2 25 | 0.1% | 0.0% | ||
| Q1 25 | 0.6% | 0.0% | ||
| Q4 24 | 0.4% | 0.0% | ||
| Q3 24 | 0.2% | 0.3% | ||
| Q2 24 | 0.5% | 0.1% | ||
| Q1 24 | 0.6% | 0.1% |
现金转化率CERTESPR
| Q4 25 | — | — | ||
| Q3 25 | 21.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.66× | — | ||
| Q4 24 | 7.51× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CERT
暂无分部数据
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
